ATyr Pharma

ATyr Pharma

ATyr Pharma (pronounced: A-Tire Far-ma) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. The company's primary focus is on the extracellular functionality and signaling pathways of tRNA synthetases.

Etymology

The name "ATyr Pharma" is derived from the scientific term "tRNA synthetases," which are a group of enzymes that play a crucial role in protein synthesis. The "A" in ATyr stands for "aminoacyl," while "Tyr" is short for "tyrosine," one of the 20 standard amino acids used by cells to synthesize proteins.

History

ATyr Pharma was founded in 2005 by Paul Schimmel, a leading scientist in the field of tRNA synthetases. The company is headquartered in San Diego, California, and has been publicly traded on the NASDAQ stock exchange since 2015.

Research and Development

ATyr Pharma's research and development efforts are primarily focused on the discovery and development of innovative medicines based on novel immunological pathways. The company's lead product candidate, ATYR1923, is a fusion protein comprised of the immuno-modulatory domain of histidyl-tRNA synthetase fused to the FC region of a human antibody. ATYR1923 is currently in clinical development for patients with pulmonary sarcoidosis.

Related Terms

• tRNA synthetases
• Pulmonary sarcoidosis
• Biotherapeutics
• Immunological pathways
• Protein synthesis
• Amino acids
• Enzymes
• Fusion protein
• Antibody
• Clinical development

External links

• Medical encyclopedia article on ATyr Pharma
• Wikipedia's article - ATyr Pharma

This WikiMD dictionary article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski